BLRX BioLineRx Ltd.

NASDAQ
$2.60

BioLineRx Ltd. (BLRX) is expected to report earnings on November 30, 2026, before the market open. The consensus earnings estimate is a loss of $0.38 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -10.3% since its last earnings release on August 31, 2026.

BioLineRx Reported Earnings
Monday, August 31, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 30
Monday · 7:00 AM ET
Earnings Whisper
-
vs ($0.38)
Rev est $380K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.69

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About BioLineRx Ltd.

Bioline Rx Ltd is a clinical stage biopharmaceutical development company engaged in identifying, in-licensing & developing therapeutic compounds in areas of central nervous system, oncology, cardiovascular, & infectious diseases, among others.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Charts powered in part by Lightweight Charts™ by TradingView.